Diabetes & Metabolism Journal

Brief Reports

Complications
Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights: Han-Sang Baek, Chaiho Jeong, Yeoree Yang, Joonyub Lee, Jeongmin Lee, Seung-Hwan Lee, Jae Hyoung Cho, Tae-Seo Sohn, Hyun-Shik Son, Kun-Ho Yoon, Eun Young Lee; Received January 22, 2024 Accepted May 13, 2024 Published online June 10, 2024; DOI: https://doi.org/10.4093/dmj.2024.0036 [Epub ahead of print]

1,072 View
85 Download

Abstract PDF PubReader ePub: One of the notable adverse effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor is diabetic ketoacidosis (DKA) often characterized by euglycemia. In this retrospective review of patients with DKA from 2015 to 2023, 21 cases of SGLT2 inhibitorassociated DKA were identified. Twelve (57.1%) exhibited euglycemic DKA (euDKA) while nine (42.9%) had hyperglycemic DKA (hyDKA). More than 90% of these cases were patients with type 2 diabetes mellitus. Despite similar age, sex, body mass index, and diabetes duration, individuals with hyDKA showed poorer glycemic control and lower C-peptide levels compared with euDKA. Renal impairment and acidosis were worse in the hyDKA group, requiring hemodialysis in two patients. Approximately one-half of hyDKA patients had concurrent hyperosmolar hyperglycemic state. Common symptoms included nausea, vomiting, general weakness, and dyspnea. Seizure was the initial manifestation of DKA in two cases. Infection and volume depletion were major contributors, while carbohydrate restriction and inadequate insulin treatment also contributed to SGLT2 inhibitor-associated DKA. Despite their beneficial effects, clinicians should be vigilant for SGLT2 inhibitor risk associated with DKA.

Complications
Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports: Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi; Diabetes Metab J. 2020;44(2):349-353. Published online April 23, 2020; DOI: https://doi.org/10.4093/dmj.2020.0091

9,626 View
201 Download
69 Web of Science
74 Crossref

Since the first case was contracted by coronavirus disease-19 (COVID-19) in Daegu, Korea in February 2020, about 6,800 cases and 130 deaths have been reported on April 9, 2020. Recent studies have reported that patients with diabetes showed higher mortality and they had a worse prognosis than the group without diabetes. In poorly controlled patients with diabetes, acute hyperglycemic crises such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) also might be precipitated by COVID-19. Thus, intensive monitoring and aggressive supportive care should be needed to inadequately controlled patients with diabetes and COVID-19 infection. Here, we report two cases of severe COVID-19 patients with acute hyperglycemic crises in Korea.

Citations

Citations to this article as recorded by

Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells
Tara M. Michaels, M. Faadiel Essop, Danzil E. Joseph
Viruses.2024; 16(8): 1243. CrossRef
Diagnosis of acute hyperglycemia based on data-driven prediction models
Xinxin Dong, Wenping Dong, Xueshan Guo
SLAS Technology.2024; 29(5): 100182. CrossRef
COVID-19 and diabetes research: Where are we now and what does the future hold? A bibliometric visualization analysis
Xunlan Zhang, Ru Wen, Hengzhi Chen, Jian Liu, Yu Wu, Min Xu, Rongpin Wang, Xianchun Zeng
Heliyon.2024; 10(18): e37615. CrossRef
Clinical Characteristics and Predictors of Mortality in Obese African-Americans with COVID-19: a Single-Center Retrospective Study
Pavani Reddy Garlapati, Suneet Kumar, Meet Patel, Bidyut Sarker, Benjamin Tiongson, Sreedhar Adapa, Sohail Abdul Salim, Mark K. Adler, Vijay Reddy Gayam
Journal of Racial and Ethnic Health Disparities.2023; 10(1): 160. CrossRef
Diabetes and the COVID-19 pandemic
Kamlesh Khunti, Jonathan Valabhji, Shivani Misra
Diabetologia.2023; 66(2): 255. CrossRef
Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
Journal of Korean Medical Science.2023;[Epub] CrossRef
COVID‐19 associated ketosis and diabetic ketoacidosis: A rapid review
Tharun T. Alamuri, Sandhya Mahesh, Kevin Dell'Aquila, Taylor Jan Leong, Rebecca Jennings, Tim Q. Duong
Diabetes, Obesity and Metabolism.2023; 25(7): 1785. CrossRef
Risks associated with acute pancreatitis (AP) with diabetic ketoacidosis (DKA) in COVID-19 patients: a literature review
Sundru Manjulata Devi, Annapurna Pamreddy, Venkata Ramana Narendra
Journal of Diabetes & Metabolic Disorders.2023; 22(1): 135. CrossRef
A Review of Hyperglycemia in COVID-19
Maryam Zahedi, Saba Kordrostami, Mohammadreza Kalantarhormozi, Marziyeh Bagheri
Cureus.2023;[Epub] CrossRef
A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19
Benjamin C. T. Field, Yue Ruan, Kinga A. Várnai, Jim Davies, Robert E. J. Ryder, Rajiv Gandhi, Sophie Harris, Dinesh Nagi, Dipesh Patel, Punith Kempegowda, Sarah H. Wild, Emma G. Wilmot, Kamlesh Khunti, Rustam Rea, Parth Narendran
Diabetes, Obesity and Metabolism.2023; 25(7): 2012. CrossRef
Diabetic Ketoacidosis in COVID-19 Patients: Clinical Characteristics and Outcomes – A Retrospective Study in a Single Tertiary Care Hospital, Dubai, United Arab Emirates
Hana AL Sughaiyer, Abeer AL Haj, Samia Murad Ibrahim Abdulrahman
Dubai Diabetes and Endocrinology Journal.2023; 29(2): 107. CrossRef
COVID-19 and diabetes
Artur Furga
Probacja.2023; 3: 235. CrossRef
COVID-19 SALGININDA DİYABET YÖNETİMİ VE HEMŞİRENİN ROLÜ
Dilek BÜYÜKKAYA BESEN, Merve DERVİŞOĞLU
Gazi Sağlık Bilimleri Dergisi.2022; 7(2): 78. CrossRef
Diabetic ketoacidosis and COVID-19: what have we learned so far?
Caio Oliveira de Sá-Ferreira, Camila Helena Macedo da Costa, João Campos Wiltgen Guimarães, Nathasha Souza Sampaio, Leticia de Moraes Lopes Silva, Larissa Paula de Mascarenhas, Nicollas Garcia Rodrigues, Talita Labonia dos Santos, Solange Campos, Esther C
American Journal of Physiology-Endocrinology and Metabolism.2022; 322(1): E44. CrossRef
COVID-19 and hyperglycaemic emergencies: perspectives from a developing country
Raisa Bhikoo, Marli Conradie-Smit, Gerhard Van Wyk, Sa’ad Lahri, Elizabeth Du Plessis, Jaco Cilliers, Susan Hugo, Ankia Coetzee
Journal of Endocrinology, Metabolism and Diabetes of South Africa.2022; 27(1): 42. CrossRef
Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients
Amr Shaaban Hanafy, Waseem M. Seleem, Hany A. Elkattawy
Clinical and Experimental Medicine.2022;[Epub] CrossRef
The COVID-19-diabetes mellitus molecular tetrahedron
Mehdi Mahmudpour, Katayoun Vahdat, Mohsen Keshavarz, Iraj Nabipour
Molecular Biology Reports.2022; 49(5): 4013. CrossRef
Diabetes and COVID-19; A Bidirectional Interplay
Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, Aikaterini Kountouri, Georgios Panagopoulos, Stavros Athanasopoulos, Eleni Korompoki, Ioannis Kalomenidis, Meletios A. Dimopoulos, Asimina Mitrakou
Frontiers in Endocrinology.2022;[Epub] CrossRef
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, Dong Xi, Tao Chen, Guang Chen, Hongwu Wang, Huiling Lu, Ming Wang, Lin Zhu, Junjian Hu, Tingting Liu, Ke Ma, Meifang Han, Xiaoping Luo
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Challenges in hyperglycemia management in critically ill patients with COVID-19
Rajesh Kethireddy, Darshan Gandhi, Asim Kichloo, Love Patel
World Journal of Critical Care Medicine.2022; 11(4): 219. CrossRef
New-Onset and Persistent Insulin-Dependent Diabetes in Patients With COVID-19: A Peruvian Experience
Anthony Ramos-Yataco, Emanuel A Salcedo Davila, Kelly Meza, Inga Harbuz-Miller
Cureus.2022;[Epub] CrossRef
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
Biomedicines.2022; 10(9): 2089. CrossRef
SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics
Shailendra Pratap Singh, Aayushi Bhatnagar, Sujeet Kumar Singh, Sanjib K. Patra, Navjot Kanwar, Abhinav Kanwal, Salomon Amar, Ranata Manna
Mini-Reviews in Medicinal Chemistry.2022; 22(16): 2102. CrossRef
Collateral damage due to COVID-19
Farhan Fazal, Nitin Gupta, Wasim Khot, Yogiraj Ray
Tropical Doctor.2021; 51(1): 126. CrossRef
Diabetic emergencies during the COVID‐19 pandemic: A case–control study
M. S. B. Huda, S. Shaho, B. Trivedi, G. Fraterrigo, L. Chandrarajan, P. Zolfaghari, T. M. Dovey, C. G. Garrett, T. A Chowdhury
Diabetic Medicine.2021;[Epub] CrossRef
Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
Rebecca J. Vitale, Yannis K. Valtis, Marie E. McDonnell, Nadine E. Palermo, Naomi D.L. Fisher
AACE Clinical Case Reports.2021; 7(1): 10. CrossRef
Outcomes and Healthcare Provider Perceptions of Real-Time Continuous Glucose Monitoring (rtCGM) in Patients With Diabetes and COVID-19 Admitted to the ICU
Kenneth W. Chow, Danielle J. Kelly, Mary C. Rieff, Patricia A. Skala, Igor Kravets, Marina M. Charitou, Eric J. Morley, Rajarsi Gupta, Joshua D. Miller
Journal of Diabetes Science and Technology.2021; 15(3): 607. CrossRef
Diabetic ketoacidosis presented with COVID-19 infection: A rare case report
Deniz Çekiç, Selçuk Yaylacı, Sümeyye Çekiç, Kubilay İşsever, Hamad Dheir, Havva Kocayiğit, Mehmet Halil Öztürk, Oğuz Karabay
Journal of Clinical Medicine of Kazakhstan.2021; 18(1): 79. CrossRef
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
Hee-Sung Kim, Minseok Kang, Gilwon Kang
BMC Infectious Diseases.2021;[Epub] CrossRef
Increased Incidence of Pediatric Diabetic Ketoacidosis After COVID-19: A Two-Center Retrospective Study in Korea
Min Jeong Han, Jun Ho Heo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 783. CrossRef
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
Andrey Santos, Daniéla Oliveira Magro, Rosana Evangelista-Poderoso, Mario José Abdalla Saad
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins’ Mimicry of Human Protein Interactions
Hale Yapici-Eser, Yunus Emre Koroglu, Ozgur Oztop-Cakmak, Ozlem Keskin, Attila Gursoy, Yasemin Gursoy-Ozdemir
Frontiers in Human Neuroscience.2021;[Epub] CrossRef
COVID-19 and Diabetic Ketoacidosis: Report of Eight Cases
Balraj Singh, Prem Patel , Parminder Kaur , Nicole Majachani, Michael Maroules
Cureus.2021;[Epub] CrossRef
Machine Learning Applied to Clinical Laboratory Data in Spain for COVID-19 Outcome Prediction: Model Development and Validation
Juan L Domínguez-Olmedo, Álvaro Gragera-Martínez, Jacinto Mata, Victoria Pachón Álvarez
Journal of Medical Internet Research.2021; 23(4): e26211. CrossRef
Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
Ines Bilic Curcic, Maja Cigrovski Berkovic, Tomislav Kizivat, Silvija Canecki Varzic, Robert Smolic, Martina Smolic
World Journal of Diabetes.2021; 12(6): 780. CrossRef
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Cyril P. Landstra, Eelco J. P. de Koning
Frontiers in Endocrinology.2021;[Epub] CrossRef
Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
James R. Gavin, Clifford J. Bailey
Diabetes Technology & Therapeutics.2021; 23(S3): S-19. CrossRef
Evaluation of Characteristics and Outcomes for Patients with Diabetic Ketoacidosis (DKA) With and Without COVID-19 in Elmhurst Queens During Similar Three-Month Periods in 2019 and 2020
Urja Patel, Linda Deluxe, Carlos Salama, Aaron Ross Jimenez, Adrian Whiting, Cedrick Lubin, Nancy Tarlin
Cureus.2021;[Epub] CrossRef
Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study
Shivani Misra, Emma Barron, Eszter Vamos, Stephen Thomas, Ketan Dhatariya, Partha Kar, Bob Young, Kamlesh Khunti, Jonathan Valabhji
The Lancet Diabetes & Endocrinology.2021; 9(10): 671. CrossRef
Diabetes mellitus and COVID-19: Understanding the association in light of current evidence
Saikat Sen, Raja Chakraborty, Pratap Kalita, Manash Pratim Pathak
World Journal of Clinical Cases.2021; 9(28): 8327. CrossRef
Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China
Shuiping Dai, Bennan Zhao, Dafeng Liu, Yongzhao Zhou, Yaling Liu, Lijuan Lan, Yalun Li, Wenxin Luo, Yilan Zeng, Weimin Li
International Journal of General Medicine.2021; Volume 14: 7207. CrossRef
Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis
Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Ali A. Rabaan, Mohammed A. Alomari, Sadiq A. Al Salman, Ahmed S. Al-Alawi, Mohammed H. Al Hassan, Hesham Alhamad, Mustafa A. Al-kamees, Fawzi M. Almousa, Hani N. Mufti, Ali M. Alwesabai, Kuldeep Dhama, Jaff
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
In-hospital Clinical Complications of COVID-19: A Brief Overview
Kevin John John, Jemimah Nayar, Ajay Kumar Mishra, Vijairam Selvaraj, Mohammad Saud Khan, Amos Lal
Future Virology.2021; 16(11): 717. CrossRef
Combined Hyperglycemic Hyperosmolar Syndrome and Diabetic Ketoacidosis Associated with COVID-19 in a Pediatric Patient
Yu Shan Tseng, Bradley Tilford, Usha Sethuraman, Katherine Cashen, Mehmet Doganay
Case Reports in Critical Care.2021; 2021: 1. CrossRef
Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19
Faraz Alizadeh, Amanda O’Halloran, Areej Alghamdi, Charlotte Chen, Maria Trissal, Avram Traum, Danielle DeCourcey
Pediatrics.2021;[Epub] CrossRef
A Complicated Case of COVID-19 and Hyperglycemic Hyperosmolar Syndrome in an Adolescent Male
Anisha Gohil, Stefan Malin, Kamal Abulebda, Tamara S. Hannon
Hormone Research in Paediatrics.2021; 94(1-2): 71. CrossRef
COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
Asirvatham Alwin Robert, Mohamed Abdulaziz Al Dawish
Current Diabetes Reviews.2021;[Epub] CrossRef
A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
Hong Nyun Kim, Jang Hoon Lee, Hun Sik Park, Dong Heon Yang, Se Yong Jang, Myung Hwan Bae, Yongkeun Cho, Shung Chull Chae, Yong-Hoon Lee
Journal of Korean Medical Science.2020;[Epub] CrossRef
Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature
Rimesh Pal, Mainak Banerjee, Urmila Yadav, Sukrita Bhattacharjee
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 1563. CrossRef
Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
Nadine E Palermo, Archana R Sadhu, Marie E McDonnell
The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): 2819. CrossRef
A Case of Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in a Patient With COVID-19
Shemitha Rafique, Fahad W Ahmed
Cureus.2020;[Epub] CrossRef
COVID’s Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19

Maureen Czick, Christine Shapter, Robert Shapter
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3169. CrossRef
Letter: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
Ja Young Jeon
Diabetes & Metabolism Journal.2020; 44(3): 480. CrossRef
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Matteo Apicella, Maria Cristina Campopiano, Michele Mantuano, Laura Mazoni, Alberto Coppelli, Stefano Del Prato
The Lancet Diabetes & Endocrinology.2020; 8(9): 782. CrossRef
Diabetes and COVID-19: Global and regional perspectives
In-Kyung Jeong, Kun Ho Yoon, Moon Kyu Lee
Diabetes Research and Clinical Practice.2020; 166: 108303. CrossRef
Hyperglycemia, Hypertriglyceridemia, and Acute Pancreatitis in COVID-19 Infection
Chiranjeevi Gadiparthi, Mehak Bassi, Balaji Yegneswaran, Sammy Ho, Capecomorin S. Pitchumoni
Pancreas.2020; 49(7): e62. CrossRef
Response: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
Diabetes & Metabolism Journal.2020; 44(3): 484. CrossRef
Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature
Pavan Kumar Reddy, Mohammad Shafi Kuchay, Yatin Mehta, Sunil Kumar Mishra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1459. CrossRef
COVID-19 and diabetes: What have we learned so far?
Nida Taher, Mohammed SB Huda, Tahseen A Chowdhury
Clinical Medicine.2020; 20(4): e87. CrossRef
High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing
Fatih Yesildal, Ferruh Kemal Isman
Turkish Journal of Biochemistry.2020; 45(5): 491. CrossRef
Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
Junghyun Noh, Hyun-Ha Chang, In-Kyung Jeong, Kun Ho Yoon
Diabetes & Metabolism Journal.2020; 44(3): 372. CrossRef
Practical considerations for pregnant women with diabetes and severe acute respiratory syndrome coronavirus 2 infection
Glenn P. Boyles, Stephen Thung, Steven G. Gabbe, Mark B. Landon, Maged M. Costantine
American Journal of Obstetrics & Gynecology MFM.2020; 2(4): 100210. CrossRef
Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series
Eleni Armeni, Umaira Aziz, Sulmaaz Qamar, Sadia Nasir, Chidambaram Nethaji, Rupert Negus, Nicholas Murch, Huw Clarke Beynon, Pierre Bouloux, Miranda Rosenthal, Sidrah Khan, Ahmed Yousseif, Ravi Menon, Efthimia Karra
The Lancet Diabetes & Endocrinology.2020; 8(8): 660. CrossRef
Development of a tablet PC-based portable device for colorimetric determination of assays including COVID-19 and other pathogenic microorganisms
Woo Sik Yoo, Hyung Soo Han, Jung Gon Kim, Kitaek Kang, Hyo-Sung Jeon, Jin-Young Moon, Hyeonmi Park
RSC Advances.2020; 10(54): 32946. CrossRef
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation
Akhil Vaid, Sulaiman Somani, Adam J Russak, Jessica K De Freitas, Fayzan F Chaudhry, Ishan Paranjpe, Kipp W Johnson, Samuel J Lee, Riccardo Miotto, Felix Richter, Shan Zhao, Noam D Beckmann, Nidhi Naik, Arash Kia, Prem Timsina, Anuradha Lala, Manish Paran
Journal of Medical Internet Research.2020; 22(11): e24018. CrossRef
COVID-19: the endocrine opportunity in a pandemic
Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Souvik Dubey, Rishi T. Guria, Chandra B. Sharma, Sanjay Kalra
Minerva Endocrinologica.2020;[Epub] CrossRef
Management of Diabetes in Coronavirus Disease 2019: Prognosis and Practical Issues
Hye Soon Kim
The Journal of Korean Diabetes.2020; 21(3): 120. CrossRef
Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19
Mohammad Shafi Kuchay, Pavan Kumar Reddy, Sakshi Gagneja, Anu Mathew, Sunil Kumar Mishra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2039. CrossRef
Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series
Ibrahim Alsadhan, Shahad Alruwashid, Maram Alhamad, Sarah Alajmi, Sara Alshehri, Eman Alfadhli, Aishah Ekhzaimy
Current Therapeutic Research.2020; 93: 100609. CrossRef
Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients
F.-J. Prado-Galbarro, C. Sanchez-Piedra, A.E. Gamiño-Arroyo, C. Cruz-Cruz
Public Health.2020; 189: 66. CrossRef
SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells
Katie C. Coate, Jeeyeon Cha, Shristi Shrestha, Wenliang Wang, Luciana Mateus Gonçalves, Joana Almaça, Meghan E. Kapp, Maria Fasolino, Ashleigh Morgan, Chunhua Dai, Diane C. Saunders, Rita Bottino, Radhika Aramandla, Regina Jenkins, Roland Stein, Klaus H.
Cell Metabolism.2020; 32(6): 1028. CrossRef
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
Amisha Wallia, Grace Prince, Emilie Touma, Malek El Muayed, Jane Jeffrie Seley
Current Diabetes Reports.2020;[Epub] CrossRef
Recovery From Acute Kidney Injury With Diabetic Ketoacidosis Following SARS-CoV-2 Infection: A Case Report and Literature Review
Chang Xu, Umer Zia
Cureus.2020;[Epub] CrossRef
The Outbreak of COVID-19 and Diabetes in Korea: “We Will Find a Way as We Have Always Done”
Kyu Chang Won, Kun Ho Yoon
Diabetes & Metabolism Journal.2020; 44(2): 211. CrossRef

Original Articles

The Classification of Diabetic Patients Presenting Diabetic Ketoacidosis: The Characteristics of Fulminant Type 1 Diabetes.: Eun Hee Jang, Jeong Eun Yi, Seung Jae Lee, Sang Hoon Chun, Ki Hyun Baek, Ki Ho Song, Soon Jib Yoo, Jong Min Lee, Kun Ho Yoon, Moo Il Kang, Kwang Woo Lee, Mee Kyung Kim; Korean Diabetes J. 2008;32(5):428-434. Published online October 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.5.428

2,936 View
56 Download
2 Crossref

Abstract PDF

BACKGROUND
The aim of the study was to classify newly diagnosed diabetic patients who initially presented with diabetic ketoacidosis (DKA) into specific types of diabetes and to describe the clinical and biochemical characteristics of patients with fulminant type 1 DM in Korea. METHODS: Using data from 4 hospitals of CMC from 1 January 1999 to 1 March 2008, we identified all patients who manifested DKA when they were first diagnosed as diabetes. Clinical and laboratory data were reviewed from medical records. RESULTS: We identified 51 newly diagnosed diabetic patients manifested DKA. Among them, 14 (27.4%) patients were classified as autoimmune type 1 DM, 8 (15.7%) as antibody negative type 1 DM, 5 (9.8%) as fulminant type 1, 16 (31.4%) as type 2 DM and 8 (15.7%) as secondary DM. Five patients who fulfilled the criteria of fulminant type 1 DM were older (32.2 +/- 10.7 vs. 15.7 +/- 4.4 years, P = 0.010), had shorter duration of symptoms (4.2 +/- 2.7 vs.16.7 +/- 15.2 days, P = 0.014) and lower stimulated C-peptide levels (0.1 +/- 0.0 vs. 0.7 +/- 0.6 ng/mL, P = 0.050) compared with patients with autoimmune type 1 DM. CONCLUSION Newly diagnosed diabetic patients presenting with DKA composed of heterogenous types of diabetes. The prevalence of fulminant type 1 diabetes among them was 9.8% and the clinical and biochemical characteristics of these patients were different from those of autoimmune type 1 DM.

Citations

Citations to this article as recorded by

A Case of Severe Diabetic Ketoacidosis in a Child with Type 2 Diabetes
Jaesung Yu, Hyunju Jin, Joontae Ko, Hoseok Kang
Journal of Korean Society of Pediatric Endocrinology.2011; 16(1): 46. CrossRef
A Case of Fulminant Type 1 Diabetes Mellitus Complicated with Ischemic Ileitis
Se-Won Oh, Ju-Ri Park, Yun-Jeong Lee, Hee-Yeong Kim, Ji-A Seo, Nan-Hee Kim, Kyung-Mook Choi, Sei-Hyun Baik, Dong-Seop Choi, Sin-Gon Kim
Journal of Korean Endocrine Society.2009; 24(2): 116. CrossRef

Clinical Characteristics and Outcomes of Diabetic Ketoacidosis at a Single Institution.: Jee In Lee, Tae Seo Sohn, Sang Ah Chang, Jung Min Lee, Bong Yun Cha, Ho Young Son, Hyun Shik Son; Korean Diabetes J. 2008;32(2):165-170. Published online April 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.2.165

2,567 View
44 Download
5 Crossref

Abstract PDF

AIMS: The aim of this study was to describe the clinical characteristics and outcomes of diabetic ketoacidosis (DKA) in Hospital for past 6 years. METHODS: We reviewed the retrospective medical records of all patients admitted with a diagnosis of DKA from 2000 to 2005 in Uijeongbu St. Mary's Hospital. Clinical characteristics including precipitating factors and hospital mortality were analyzed. RESULTS: Seventy-eight patients (78 episodes) fulfilled criteria for inclusion in this study. Their mean age was 41.89 years. 66 episodes had a prior history of diabetes but DKA was the initial presentation in 12 episodes. 24.4% were on no treatment, 14.1% were using oral hypoglycemic agents and 53.8% were on insulin. Poor glycemic control were the most common precipitating factor (56.4%). There were 3 deaths. CONCLUSION: Our report is similar with past reports of DKA in Korea. but it is different that poor glycemic control is most common precipitating factor and mortality rate are lower than past reports. This observation suggests that many cases of DKA can be prevented by better access to medical care, proper education, and effective communication with a health care provider.

Citations

Citations to this article as recorded by

Clinical and Laboratory Characteristics of Pediatric Diabetic Ketoacidosis: A Single-Center Study
Iee Ho Choi, Min Sun Kim, Pyoung Han Hwang, Dae-Yeol Lee
The Journal of Korean Diabetes.2017; 18(3): 193. CrossRef
Clinical and Biochemical Characteristics of Elderly Patients With Hyperglycemic Emergency State at a Single Institution
Yun Jae Shin, Dae In Kim, Dong Won Lee, Beung Kwan Jeon, Jung Geun Ji, Jung Ah Lim, Young Jung Cho, Hong Woo Nam
Annals of Geriatric Medicine and Research.2016; 20(4): 185. CrossRef
Evaluation of the Clinical Significance of Ketonuria
Hae-Won Jung, Ile-Kyu Park
Laboratory Medicine Online.2012; 2(1): 15. CrossRef
A Case of Severe Diabetic Ketoacidosis in a Child with Type 2 Diabetes
Jaesung Yu, Hyunju Jin, Joontae Ko, Hoseok Kang
Journal of Korean Society of Pediatric Endocrinology.2011; 16(1): 46. CrossRef
Clinical Characteristics of Patients with Hyperglycemic Emergency State Accompanying Rhabdomyolysis
Soo Kyoung Kim, Jong Ha Baek, Kyeong Ju Lee, Jong Ryeal Hahm, Jung Hwa Jung, Hee Jin Kim, Ho-Su Kim, Sungsu Kim, Soon Il Chung, Tae Sik Jung
Endocrinology and Metabolism.2011; 26(4): 317. CrossRef

Case Reports

A Case of Diabetic Ketoacidosis in Gestational Diabetes Mellitus.: Myung Hwan Kim, Eui Dal Jung, Seung Pyo Hong, Gyu Hwan Bae, Sun Young Ahn, Eon Ju Jeon, Seong Yeon Hong, Ji Hyun Lee, Ho Sang Son; Korean Diabetes J. 2007;31(4):368-371. Published online July 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.4.368

2,263 View
40 Download

Abstract PDF: Gestational diabetes mellitus (GDM) is defined as glucose intolerance of variant severity with onset or first recognition during present pregnancy. Recently the prevalence of GDM in Korean has reported as 1.7~4.0%. Diabetic ketoacidosis is a serious metabolic complication of diabetes with high mortality if undetected. Its occurrence is very rare in gestational diabetes patients, but is harmful to fetal and maternal health. A 26 years-old pregnant woman was admitted at 37 weeks gestation because of progressive generalized weakness, anorexia and weight loss. Initial physical examination reveals that she had been dehydrated, and blood pressure 130/80 mmHg, pulse rate 100/min, respiratory rate 20/min, and body temperature was 36.9 degrees C. Serum glucose was 545 mg/dL, pH 7.282, HCO3- 10.5 mmol/L, urine ketone 3+, urine glucose 2+ when initial laboratory work was done. She was treated with intravenous fluid and insulin under the impression of diabetic ketoacidosis. Her delivery was performed after 24 hours from admission because of suggestive fetal distress. After recovery, she is being treated with insulin at outpatient department. We experienced a appropriately treated case of diabetic ketoacidosis in pregnant woman with GDM, and report it with a literature review.

A Case of Ketosis-Prone Type 2 Diabetes Mellitus.: Dong Lim Kim, Suk Kyeong Kim, Kee Ho Song; Korean Diabetes J. 2007;31(3):293-296. Published online May 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.3.293

2,183 View
20 Download
1 Crossref

Abstract PDF

Ketosis-prone type 2 diabetes (KPD) has been characterized as diabetes with severe insulin deficiency at diagnosis associated with ketosis or ketoacidosis without a precipitating cause. Improvement in beta-cell function and insulin sensitivity by aggressive diabetic management could allow discontinuation of insulin therapy within a few month of therapy. These subjects are usually obese, have a strong family history of diabetes, absence of beta-cell autoimmune markers and lack of human leukocyte antigen genetic association. This clinical presentation has been reported primarily in African and African Americans, but rare in Asian and white person. We recently experienced a case of KPD in Korea and present it with literature review.

Citations

Citations to this article as recorded by

A Case of Autoantibody-Positive Ketosis-Prone Diabetes Mellitus
Bora Yoon, Gyuri Kim, Jae Hyun Bae, Yu Jung Yun, Yong Ho Lee, Byung Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
The Journal of Korean Diabetes.2016; 17(1): 60. CrossRef

A Case of Acromegaly Presenting with Diabetic Ketoacidosis.: Jin Dong Kim, Tae Seo Sohn, Jee In Lee, Jick Hwan Hah, Yun Hwa Jung, Jung Min Lee, Sung Min Nam, Seung Won Lee, Hyun Shik Son; Korean Diabetes J. 2006;30(4):312-315. Published online July 1, 2006; DOI: https://doi.org/10.4093/jkda.2006.30.4.312

2,153 View
18 Download

Abstract PDF: In patients with acromegaly, glucose intolerance and diabetes mellitus are one of the frequent manifestations. And the type of diabetes in these patients is usually non-insulin dependent type secondary to insulin resistance caused by growth hormone excess. Therefore, the diabetes mellitus in these patients dose not tend to develop diabetic ketoacidosis. But we experienced and presented the case of a patient with acromegaly hospitalized due to the diabetic ketoacidosis without overt clinical manifestations of acromegaly. This case of acromegaly showed that growth hormone excess could cause diabetic ketoacidosis in the presence of relative insulin deficiency.

Two Cases of Diabetic Ketoacidosis Associated with Atypical Antipsychotics.: Seung Hee Lee, Kum Ho Yi, Eun A Kim, Seong Bin Hong, Moon Suk Nam, Yong Seong Kim; Korean Diabetes J. 2005;29(6):566-570. Published online November 1, 2005

1,023 View
23 Download

Abstract PDF: Atypical antipsychotics have been widely used for the management of patients with schizophrenia and other psychotic disorders. However, they may be associated with a greater risk of metabolic abnormalities than others, including weight gain, hyperlipidemia, and new-onset type 2 diabetes mellitus or diabetic ketoacidosis (DKA). We report two cases of reversible DKA and new-onset DM that developed in patients treated with atypical antipsychotics. A 42-year-old male patient with schizophrenia who was on olanzapine admitted to the hospital because of DKA. He had been taking olanzapine for 5 months. Five months before the admission, his fasting serum glucose levels were 109 m/dL. Another 34-year-old male with no previous history of diabetes mellitus was admitted to the hospital and subsequently diagnosed with DKA. The patient had been taking risperidone. Clinicians should monitor blood glucose concentrations periodically in patients taking atypical antipsychotics.

A Case of Diabetic Ketoacidosis in a GAD Antibody-positive Diabetes Patients who Recently Experienced Hyperglycemic Hyperosmolar State.: Jang Won Son, Seok Hong Lee, Jung Ahn Lee, Jaetaek Kim, Yeon Sahng Oh, Soon Hyun Shinn; Korean Diabetes J. 2005;29(3):267-270. Published online May 1, 2005

1,113 View
20 Download

Abstract PDF: The term latent autoimmune diabetes in adults(LADA) was introduced to define adult diabetic patients who initially do not require insulin, but they have the immune markers of type 1 diabetes and in a number of cases, these patients progress to insulin dependency. LADA patients have several features of classic type 1 diabetes in addition to islet cell antibody positivity, including high rates of HLA-DR3 and DR4. We describe here a case of a patient with a diagnosis of LADA who, having been diagnosed with type 2 diabetes, was affected with diabetic ketoacidosis. In April 2000, a 65-year-old man was admitted to Chung-Ang University Hospital due to his decreased cognitive ability. The patient was diagnosed with type 2 diabetes 30-years ago and he was diagnosed 6-month ago as being in a hyperglycemic hyperosmolar state. He was positive for antibodies against GAD(anti-GAD, 31U/mL). His weight was 70kg, height 167cm, BMI 25 kg/m2 and the blood pressure was 86/52mmHg. No abnormalities on the physical examination were found. His acid-base balance was pH 6.937, serum bicarbonate 2.2mmol/L and the anion gap 38; he also had a strong positive reaction for ketones in his urine and serum. During half a year, the fasting C-peptide level decreased from 0.65nmol/L to 0.13nmol/L, which means the rapid progression of beta-cell destruction. Intensive treatment of LADA with insulin may improve this type of patients' quality of life, and so potentially save the beta-cell function and perhaps lessening the risk of a hyperglycemic crisis

Original Article

A Case of MELAS(Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like Episodes) Syndrome Manifested by Diabetic Ketoacidosis.: Sung Hoon Jung, Eun Jung Kim, So Hi Im, Kang Ju, Kang hyun Choi, Seung Hyun Ko, Yu Bae Ahn, Ki Ho Song, Ho Young Son, Sung Kyung Park, Jeong Su Jun; Korean Diabetes J. 2004;28(3):231-237. Published online June 1, 2004

1,563 View
29 Download

Abstract PDF: MELAS(mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes) syndrome is a rare cause of mitochondrial encephalomyopathy, with variable clinical features, such as encephalomyopathy, lactic acidosis, stroke, diabetes, short stature, sensorineural hearing loss and basal ganglia calci-fication, etc. It can be confirmed by molecular genetic analysis that reveals the mitochondrial A3243G point mutation. Among the clinical manifestations in MELAS syndrome, diabetes mellitus is associated with impaired insulin secretion and often misdiagnosed type 1 diabetes. Herein, a rare case for the MELAS syndrome, with diabetes mellitus that came from ketoacidosis, is introduced. A 21-year-old woman, carried to the emergency department had a stuporous mentality. She was thin(BMI 16.1kg/m(2)), and had difficulty with her hearing capacity. According to the initial laboratory results, she showed the metabolic acidosis, hyperglycemia, ketonemia, and ketonuria. She was diagnosed as diabetic ketoacidosis and treated with insulin and hydration. Brain imaging from MRI, and a CT scan showed basal ganglia calcification, hemorrhagic infarction and diffuse brain atrophy. The markers for beta-cell autoimmunity were negative. Her electromyography suggested proximal myopathy. In addition, a molecular genetic analysis identified A3243G point mutation in the peripheral blood leukocytes from her, her mother and her sister.

Case Report

A Case of Severe Hypertriglyceridemia with Diabetic Ketoacidosis.: Dong Seop Choi, Jeong Heon Oh, Ie Byung Park, Jin Won Kim, Kyung Mook Choi, Yong Hyun Kim, Nan Hee Kim, Sang Jin Kim, Sei Hyun Baik; Korean Diabetes J. 1999;23(5):715-721. Published online January 1, 2001

1,165 View
24 Download

Abstract PDF: Severe hypertriglyceridemia exceeding 5.6 mmol/L in diabetic ketoacidosis occasionally occur in patients with type 1 diabetes mellitus. The pattern of dyslipidemia is usually Fredrickson classification type lV. But it also exists in type III and type V. However, extreme triglyceridemia, triglyceride level exceeds 22.6 mmol/L, occur rarely in the modern era of insulin therapy. And the pattern is usually Fredrickson type I. The severe hypertriglyceridemia in diabetic ketoacidosis is mainly due to lipoprotein lipase deficiency, and secondly to insulin deficiency. The severity usually improves with insulin replacement. In patients with extreme hypertriglyceri-demia, serum electrolyte values of the patients are fallaciously low, and it leads to the misinterpretation of biochemical results and to the inappropriate treatment. We reported a case of a 25 years old female patient with diabetic ketoacidosis and extreme hypertriglyceridemia. At admission, the color of her serum was milky, her plasma triglyceride concentration was 144.7 mmol/L (12864 mg/dL), cholesterol was 25.5 mmol/L (982 mg/dl), and HDL-cholesterol was 0.77 mmol/L (40 mg/dL). The biochemical values at admission could not be measured. Empirical therapy was administered with the use of insulin and fluid. After the initial treatment with insulin and fluid, plasma triglyceride declined rapidly and was nearly normal after 72 hours. We also measured fasting blood glucose concentration and lipid profiles from her father and two sisters. Their plasma glucose and lipid profiles were normal.

Original Article

Metabolic Factors Influencing Serum Potassium Levels in Diabetic Ketoacidosis.: Sung Jin Kim, Seung Oh Suh, Sung Hee Ihm, Hyun Kyu Kim, Doo Man Kim, Jae Myung Yoo, Moon Gi Choi, Hyung Joon Yoo; Korean Diabetes J. 1999;23(5):661-668. Published online January 1, 2001

1,110 View
21 Download

Abstract PDF: BACKGROUND
The serum K level is normal or high in the majority of patients with diabetic ketoacidosis (DKA) despite significant total body K+ deficits. This might be due to the combined effects of severe acidosis, insulin deficiency, volume contraction, hyperglycemia and hypertonicity that usually accompany DKA. The aim of this study was to investigate the most likely determinants of the serum K+ levels among metabolic derangements observed in DKA patients. METHODS: The subjects were 88 DKA patients who had normal or high initial serum K+ levels. We anaylzed the correlation between initial serum K' levels and metabolic parameters (arterial pH, arterial HCO(3-) level, anion gap, serum glucose level, osmolality, BUN and fasting C-peptide levels), by simple linear regression analysis and stepwise multiple regression analysis. RESULT: Serum K+ levels correlated significantly with initial arterial pH(r=-0.38, p<0.001), HCO(3-) (r=-0.35, p<0.001), anion gap(r=0.21, p<0.05), serum glucose (r=0.22, p<0.05) and fasting C-peptide (r=-0.33, p<0.05) levels. Among these, arterial HCO(3-), serum glueose and fasting C-peptide levels had significant and independent effects on serum K+ levels. These levels could account for about 33% of the observed variance in serum K+ levels. CONCLUSION: These results suggest that metabolic acidosis and hyperglycemia in DKA, which result primarily from insulin deficit, are the main determinants of increased serum K+ levels.

First
Prev
Page of 1
Next
Last

Search